Search clinical trials for: NOTCH pathway

Total 1456 results

National Cancer Institute (NCI)

Completed

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

Desmoid Tumors | Aggressive Fibromatosis

United States
Cellestia Biotech AG

Terminated

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Breast Cancer | Adenoid Cystic Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Osteosarcoma | Non-hodgkin Lymphoma | Glomus Tumor, Malignant | T-ALL

United States, Spain, Korea, Republic of, Germany, France, Switzerland
SpringWorks Therapeutics, Inc.

Active, not recruiting

Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (DeFi)

Desmoid Tumor | Aggressive Fibromatosis

United States, Belgium, Germany, Canada, Italy, Netherlands, United Kingdom
National Cancer Institute (NCI)

Completed

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma

Stage IV Skin Melanoma | Recurrent Melanoma

United States
National Cancer Institute (NCI)

Terminated

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Unspecified Adult Solid Tumor, Protocol Specific | HER2-positive Breast Cancer | Recurrent Melanoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast... and other conditions

United States
University of Miami

Terminated

Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients

Esophageal Cancer

United States
National Cancer Institute (NCI)

Completed

Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

Recurrent Uterine Corpus Sarcoma | Chondrosarcoma | Recurrent Osteosarcoma | Gastrointestinal Stromal Tumor | Clear Cell Sarcoma of the Kidney | Metastatic Osteosarcoma | Ovarian Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage III Uterine Sarcoma | Stage IV Adult... and other conditions

United States
Tianjin Medical University Cancer Institute and...

Withdrawn

Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases

Thymoma | Autoimmune Disease

China
National Cancer Institute (NCI)

Terminated

Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Withdrawn

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

Sarcoma | Lymphoma | Brain Neoplasms | Osteosarcoma | Wilm's Tumor

United States
Washington University School of Medicine

Completed

The Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction in Rural Malawian Children 1-3 Year Olds

Environmental Enteropathy

Malawi
National Cancer Institute (NCI)

Terminated

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
National Cancer Institute (NCI)

Terminated

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer

Canada
National Cancer Institute (NCI)

Withdrawn

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer | Adenocarcinoma of the Colon

United States
University Hospital, Montpellier
Institut de Recherche en Cancérologie de Montpellier (IRCM)

Unknown

Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma (NOTCH)

Lung Adenocarcinoma

France
National Cancer Institute (NCI)

Terminated

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant Melanoma

United States
National Cancer Institute (NCI)

Terminated

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain Tumor

United States
National Cancer Institute (NCI)
M.D. Anderson Cancer Center

Terminated

RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
Cancer Research UK

Completed

MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery

Pancreatic Cancer

United Kingdom
National Cancer Institute (NCI)

Terminated

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Merck Sharp & Dohme LLC

Terminated

A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Leukemia, Lymphoblastic, Acute, T-cell | Myelogenous Leukemia
Merck Sharp & Dohme LLC

Completed

A Notch Signalling Pathway Inhibitor for Patients With Advanced Breast Cancer (0752-014)

Advanced Breast Cancer | Other Solid Tumors
National Cancer Institute (NCI)

Completed

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors

Adult Solid Neoplasm

United States
National Cancer Institute (NCI)

Completed

Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
National Cancer Institute (NCI)

Completed

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States, Canada
National Cancer Institute (NCI)

Terminated

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Unspecified Childhood Solid Tumor, Protocol Specific | Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Recurrent Childhood Acute Lymphoblastic Leukemia | T-cell Large Granular Lymphocyte Leukemia | T-cell Childhood Acute Lymphoblastic... and other conditions

United States, Canada
National Cancer Institute (NCI)

Completed

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Stage III Renal Cell Cancer | Recurrent Endometrial Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IV Endometrial Carcinoma | Stage III Endometrial Carcinoma | Endometrial Papillary Serous Carcinoma

Canada
National Cancer Institute (NCI)

Completed

RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

United States
National Cancer Institute (NCI)

Completed

Gamma-Secretase Inhibitor RO4929097 in Treating Patients With Metastatic or Unresectable Solid Malignancies

Unspecified Adult Solid Tumor, Protocol Specific

Canada
National Cancer Institute (NCI)

Completed

Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer

Canada
National Cancer Institute (NCI)

Terminated

RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer

Adenocarcinoma of the Pancreas | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer

United States
National Cancer Institute (NCI)

Terminated

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

RO4929097 in Treating Patients With Recurrent Invasive Gliomas

Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Tumor | Adult Brain Stem Glioma

Canada
National Cancer Institute (NCI)

Withdrawn

RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery

Stage IV Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Xie Kangjie

Recruiting

Predictive Effect of TGF-β Combined With INS-PI3K-AKT Signaling Pathway Related Proteins (ADNP, MAP6, Pgc-1α) for POD on Diabetes Patients

Diabetes | Postoperative Delirium

China
Mayo Clinic

Not yet recruiting

NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Cholangiocarcinoma | Refractory Cholangiocarcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Advanced Cholangiocarcinoma

United States
Hitit University

Recruiting

Schroth Treatment and Proprioception Pathway

Adolescent Idiopathic Scoliosis

Turkey
University of Alberta

Not yet recruiting

Pharmacist Case Finding and Intervention for Vascular Prevention Trial (PRxOACT)

Cardiovascular Disease | Diabetes | Dyslipidemia | Blood Pressure | Cardiovascular Risk Factors
Assistance Publique Hopitaux De Marseille

Recruiting

Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway (BIOCEPTION)

Lung Cancer | Smoking-related Pathology | Atheroma | Non-progressive Cancer > 5 Years

France
The Cleveland Clinic

Not yet recruiting

Engaging Patients in Prenatal Genetic Testing Decisions as a Pathway to Improve Obstetric Outcomes (OPUS)

Prenatal Disorder

United States
Mayo Clinic

Not yet recruiting

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial (DIVINE)

Recurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage IVB Prostate Cancer AJCC v8 | Recurrent Castration-Sensitive Prostate Carcinoma

United States
University of Alberta
Alberta Innovates Health Solutions

Not yet recruiting

Digital Health Pathway for Children With Medical Complexity Requiring Tracheostomy (DECIDE-T)

Tracheostomy

Canada
Stony Brook University
Massachusetts General Hospital; Mclean Hospital

Recruiting

Use of Ketosis in Modulating Metabolic Pathways in Bipolar Disorder

Bipolar Disorder | Bipolar Disorder Type 1

United States
University Hospital, Toulouse
Janssen, LP; Ligue contre le cancer, France

Not yet recruiting

Real-life Management of Patients Eligible for CAR-T Cell Therapy (CARAVAGE)

Hemopathy

France
Medical College of Wisconsin

Not yet recruiting

Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

Breast Cancer

United States
University of Alabama at Birmingham

Not yet recruiting

Establishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND

Convulsion, Non-Epileptic | Functional Neurological Disorder | Functional Seizure

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
Chinese University of Hong Kong

Not yet recruiting

To Evaluate an MRI-based Optimized Prostate Cancer Diagnostic Pathway Powered by Artificial Intelligence

Prostate Cancer

Hong Kong
Institut Jean-Godinot
Université de Reims Champagne-Ardenne

Not yet recruiting

Development of a Questionnaire on Patients' Perception of Their Oncology Care Pathway (Onco-PREMs) (OncoPREMs)

Cancer
University of Michigan
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Not yet recruiting

Guideline to Implementation: A Rapid Clinical Care Pathway to Care for Patients Affected by Chronic Constipation

Constipation

United States

Search clinical trials for: NOTCH pathway

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations